Navigation Links
Thomson Scientific Announces BONDplus for Biological Researchers
Date:9/10/2007

Life Science Platform Delivers Real Time, Comprehensive and Seamless Public and Proprietary Biological Sequence, Interaction and Patent Information

PHILADELPHIA, Sept. 10 /PRNewswire-FirstCall/ -- Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, announced today the release of BONDplus, an integrated, web-based data platform to address the information and analytic needs of biological researchers.

Compiled from 15 assembled resources including GenBank, RefSeq, Entrez Gene and UniProtKB/Swiss-Prot, BONDplus allows researchers to move beyond the genome and leverage publicly available biological sequence data, BINDplus biomolecular interaction data as well as GENESEQ, a value added database of patented biological sequences. The platform allows novel insights into biological research including target-based discovery and rational drug design.

"Today's life science data management faces considerable hurdles due to years of fragmented and non-standardized production of biological data," said Jon Brett-Harris, executive vice president of pharmaceutical and chemical markets at Thomson Scientific. "Since solutions are frequently focused on one data type or in a niche area, an integrated platform can provide a distinct competitive advantage, allowing scientists not only to access public domain data, but also to integrate their own proprietary data and value-added Thomson Scientific data in a consistent and user-friendly format."

BONDplus provides an intuitive and value-added resource for any researcher by uniting the genomic, proteomic and metabolomic research communities around one comprehensive platform. The subscription service provides information from over 15 assembled resources including BINDplus and GENESEQ in addition to pre- computed data sets with BLAST functionality, visualization tools and over 80 million in public domain sequences.

A leading provider of life science research information, Thomson serves primary, secondary and tertiary data types, ranging from proteins and small molecules to gene and protein expression and more complex data types such as toxicology/efficacy data, biomarker, interaction and pathway information.

For more information on BONDplus, please visit: http://scientific.thomson.com/bondplus/

About The Thomson Corporation

The Thomson Corporation (http://www.thomson.com) is a global leader in providing essential electronic workflow solutions to business and professional customers. With operational headquarters in Stamford, Conn., Thomson provides value-added information, software tools and applications to professionals in the fields of law, tax, accounting, financial services, scientific research and healthcare. The Corporation's common shares are listed on the New York and Toronto stock exchanges (NYSE: TOC; TSX: TOC).

Thomson Scientific is a business of The Thomson Corporation. Its information solutions assist professionals at every stage of research and development-from discovery to analysis to product development and distribution. Thomson Scientific information solutions can be found at scientific.thomson.com.


'/>"/>
SOURCE Thomson Scientific
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Scientific markers of aging described
2. A Settlement Over Stem Cell Controversy Through Scientific Research
3. A Scientific Explanation For Out Of Body Experience
4. PUFA Good For Heart: Gets The Scientific Seal
5. Forensic Phonetics – Scientific Solution for Legal Problem
6. Old Indian Advice Has A Scientific Backing Now!
7. India To Highlight Its Scientific Achievements
8. Thumbs up in weight loss for vegetarian diets: scientific review
9. Scientific Research in a War Zone
10. Unscientific Depression Drugs aplenty in Health Stores
11. No Scientific Evidence to Support Drug Safety Recommendations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: